Vairavan, Srinivasan
Rashidisabet, Homa
Li, Qingqin S.
Ness, Seth
Morrison, Randall L.
Soares, Claudio N.
Uher, Rudolf
Frey, Benicio N.
Lam, Raymond W.
Kennedy, Sidney H.
Trivedi, Madhukar
Drevets, Wayne C.
Narayan, Vaibhav A.
Funding for this research was provided by:
Janssen Research & Development, LLC based on the license agreement
Article History
Received: 3 April 2023
Accepted: 10 October 2023
First Online: 30 October 2023
Competing interests
: The authors declare no competing non-financial interests but the following competing financial interests. SV, SN, WCD, and QSL are employees of Janssen Research & Development, LLC, of Johnson & Johnson, and may hold equity in Johnson & Johnson. RM and VAN were employees of Janssen Research & Development, LLC when the study was conducted; RM is now retired and a consultant to Janssen Research & Development, LLC. VAN is currently affiliated with Davos Alzheimer’s Collaborative. MT is or has been an advisor/consultant and received fee from (lifetime disclosure): Abbott Laboratories, Inc., Abdi Ibrahim, Akzo (Organon Pharmaceuticals Inc.), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, CME Institute of Physicians, Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, Fabre Kramer Pharmaceuticals, Inc., Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC, Janssen Pharmaceutica Products, LP, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Inc., Pfizer Inc., PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd., Sepracor, SHIRE Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst Laboratories. In addition, he has received grants/research support from: Agency for Healthcare Research and Quality (AHRQ), Cyberonics, Inc., National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health and National Institute on Drug Abuse. RWL has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from: Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Healthy Minds Canada, Janssen, Lundbeck, Lundbeck Institute, Medscape, Michael Smith Foundation for Health Research, MITACS, Myriad Neuroscience, Ontario Brain Institute, Otsuka, Pfizer, Sanofi, Unity Health, Vancouver Coastal Health Research Institute, and VGH-UBCH Foundation. CNS has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from Canadian Institutes of Health Research, Lundbeck, Ontario Brain Institute, Otsuka, Pfizer, Bayer and Eisai. SHK has received research funding or honoraria from the following sources: Abbott, Alkermes, Allergan Abbvie, Brain Canada, Canadian Institutes for Health Research, Janssen, Lundbeck, Lundbeck Institute, Ontario Brain Institute, Ontario Research Fund, Otsuka, Pfizer, Servier, Sunovion and Xian-Janssen and holds stock in Field Trip Health. HR, BNF, and RU report no competing financial or non-financial interests.